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Background: Central arterial stiffness represents a well-established predictor of cardiovascular disease. Decreased
circulating endothelial progenitor cells (EPCs), increased asymmetric dimethyl-arginine (ADMA) levels, traditional
cardiovascular risk factors and insulin resistance have all been associated with increased arterial stiffness. The
correlations of novel and traditional cardiovascular risk factors with central arterial stiffness in prediabetic individuals
were investigated in the present study.
Methods: The study population consisted of 53 prediabetic individuals. Individuals were divided into groups of
isolated impaired fasting glucose (IFG), isolated impaired glucose tolerance (IGT) and combined IGT-IFG. Age, sex,
family history of diabetes, smoking history, body mass index (BMI), waist to hip ratio (WHR), waist circumference
(WC), blood pressure, lipid profile, levels of high sensitive C-reactive protein (hsCRP), glomerular filtration rate (GFR),
and history of antihypertensive or statin therapy were obtained from all participants. Insulin resistance was
evaluated using the Homeostatic Model Assessment (HOMA-IR). Carotid -femoral pulse wave velocity was used as
an index of arterial stiffness. Circulating EPC count and ADMA serum levels were also determined.
Results: Among studied individuals 30 (56.6%) subjects were diagnosed with isolated IFG, 9 (17%) with isolated IGT
(17%) and 14 with combined IFG-IGT (26.4%). In univariate analysis age, mean blood pressure, fasting glucose, total
cholesterol, LDL cholesterol, and ADMA levels positively correlated with pulse-wave velocity while exercise and GFR
correlated negatively. EPC count did not correlate with PWV. In multivariate stepwise regression analysis PWV
correlated independently and positively with LDL-Cholesterol (low density lipoprotein) and ADMA levels and
negatively with exercise.
Conclusions: Elevated ADMA and LDL-C levels are strongly associated with increased arterial stiffness among
pre-diabetic subjects. In contrast exercise inversely correlated with arterial stiffness.
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Pre-diabetes confers an increased risk for developing
type ΙΙ diabetes and cardiovascular disease [1]. Both
isolated impaired fasting glucose (IFG) and impaired
glucose tolerance (IGT) are characterized by insulin
resistance and impaired insulin secretion [2] and insulin
resistance constitutes a major cardiovascular risk factor
in diabetic and obese patients. A common pathway, by
which insulin resistance leads to increased cardiovascu-
lar risk, is increased arterial stiffness, which is directly
linked to the development of isolated systolic hyperten-
sion, increase in cardiac afterload and finally impairment
of coronary perfusion [3]. As a consequence of the
above, central arterial stiffness is a well-established inde-
pendent predictor of cardiovascular events [4]. Large-
scale epidemiological studies have well established the
independent correlation of insulin resistance with arterial
stiffness [5], whereas the latter appears to increase con-
sistently with deterioration of glucose tolerance status [6].
Therefore, impaired fasting glucose (IFG), impaired glucose
tolerance (IGT), and frank diabetes are all states of
increased arterial stiffness [6].
At the molecular level, insulin resistance is characterized
by impairment of Phosphoinositide 3-kinase (PI 3-kinase)
signaling pathway, whereas the Mitogen-Activated Protein
Kinase (MAPK) pathway is unaffected. Decreased PI
3-kinase signaling leads to attenuated induction of endo-
thelial nitric oxide synthase (eNOs) and decreased NO
(nitric oxide) production. Additionally, MAPK overdrive
results in increased smooth muscle cell proliferation and
concurrent induction of numerous growth factors and
other inflammatory mediators, all of which contribute to
endothelial cell dysfunction and arterial stiffness aggra-
vation [7]. Insulin resistance has also been reported to
up-regulate expression of vascular angiotensin II type 1
receptor which alters extracellular matrix homeostasis
leading to accumulation of extracellular matrix proteins
which further propagates arterial stiffness [8]. Finally
chronic hyperglycemia leads to increased formation of
advanced glycation end products (AGEs) which accumu-
late in the arterial wall, covalently modify and link extra-
cellular proteins leading to fibrosis and increased arterial
stiffness [9,10].
Although arterial stiffness has been mainly attributed
to alterations of the tunica media (elastin/collagen ratio),
intima can also influence arterial elasticity through
endothelial cell dysfunction, with consequent reduced
NO bioavailability and increased vascular smooth muscle
tone [11]. In the above context, restoration of endothe-
lial monolayer by endothelial progenitor cells (EPCs) is
crucial for maintaining unimpeded endothelial integrity
[12]. Recruitment of EPC from bone marrow is NO
mediated and seems to be attenuated in pre-diabetic
patients [13] and reduced numbers of EPCs have beenassociated with impaired arterial elasticity among
diabetic patients [13,14]. PI 3-kinase pathway is pivotal
in the regulation of EPC proliferation, recruitment and
mobilization and its impairment in insulin resistance
states seems to be a major molecular pathway implicated
in reduced EPC counts and increased arterial stiffness [15].
Asymmetric dimethyl-l-arginine (ADMA), an endogen-
ous nitric oxide synthase inhibitor has been associated with
endothelial cell dysfunction, decreased EPC proliferation,
mobilization and recruitment [16,17] and vascular
stiffening [18]. ADMA levels are increased in individuals
with insulin resistance and diabetes and hyperglycemia
directly increases ADMA levels through decreased ac-
tivity of dimethylarginine dimethylaminohydrolase (DDAH)
[19-21].
As the prevalence of pre-diabetes rises with age, there
is also an age-related increase in arterial stiffness. Early
identification of novel and traditional risk factors
associated with increased stiffness is crucial since their
control will directly lead to improvement of arterial
elasticity. Although a great number of studies has shed
light on the correlation between arterial stiffness and
established traditional cardiovascular risk factors, there
is a lack of studies investigating the effect of novel
cardiovascular risk factors, such as ADMA and EPCs, on
arterial stiffness, especially in the pre-diabetic state.
In the present study we investigated the relationship
between cardiovascular risk factors, novel and traditional,
and arterial stiffness as measured by means of PWV, with
emphasis placed on novel risk factors, as ADMA and
EPCs, among subjects with pre-diabetes.
Materials and methods
This cross sectional clinical study was conducted in a
tertiary urban Greek hospital. The study population
consisted of general population subjects recruited in the
outpatient diabetes clinic and internal medicine depart-
ments of Tzanio General Hospital, Piraeus Greece. The
study was approved by the Institution Ethics committee
of the hospital and informed consent was obtained on
all cases. All participants underwent a75gr oral glucose
tolerance test (OGTT) to determine glucose tolerance
status according to the criteria of the American Diabetes
Association [22]. IFG diagnosis was based on fasting
plasma glucose (FPG) value ≥ 100 mg/dL and < 126 mg/dL.
Diagnosis of IGT was based on serum glucose concentra-
tion 2-h PG ≥ 140 mg/dL and < 200 mg/dL.
Initially, 80 newly diagnosed subjects with pre-diabetes
were enrolled. Three of them did not consent to partici-
pation in the study and 24 were not included due to the
exclusion criteria adopted (see below) leaving finally 53
pre-diabetic subjects that were finally enrolled. Selected
individuals were subsequently divided into groups of
isolated IFG, isolated IGT and combined IGT-IFG. For
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mined at baseline: age, sex, family history for diabetes,
smoking history, Body Mass Index (BMI), waist to hip
ratio (WHR), waist circumference, waist-to-height ratio,
(WHtR) blood pressure (systolic and diastolic), total
cholesterol, low density lipoprotein (LDL)-cholesterol,
high density lipoprotein (HDL)-cholesterol, and glom-
erular filtration rate (GFR) using the Cockroft-Gault
formula.
Insulin resistance was evaluated using the homeostasis
model assessment for insulin resistance (HOMA-IR).
C-reactive protein (hs-CRP) was measured with
high-sensitivity methods using nephelometry (BN II
Nephelometer-Siemens).
Exclusion criteria for pre-diabetic subjects included:
coronary artery disease, peripheral arterial disease,
history of stroke, history of infection in the last month,
autoimmune disease, hyper- or hypothyroidism, excess
alcohol intake (> 14 drinks/wk for women and
> 20 drinks/wk for men), creatinine clearance less than
60 mL/min, secondary hypertension, chronic heart
failure (NYHA class III and IV), history of malignancy,
hormone replacement therapy and intake of oral contra-
ceptives. No participant was treated with metformin
within three months prior to study entry.
Cardiovascular disease was excluded by medical his-
tory questionnaire, physical examination and confirmed
by electrocardiography, treadmill testing, and thallium
201 cardiac scintigraphy when applicable. Individuals
receiving antihypertensive treatment were considered
hypertensive regardless of blood pressure measurements.
Use of lipid-lowering, medication was also recorded.
Participants were classified as exercisers if they reported
moderate physical activity (walking at least 150 minutes/
week) or otherwise sedentary. Vigorous physical activity
was not reported by any participant.
Evaluation of ADMA concentration
Venous blood samples were collected from participants
after overnight fast, by venipuncture of the antecubital
vein, into serum tubes. Samples were centrifuged at
10.000 x g for 10 min and the supernatant serum was
collected and stored at -20°C. The quantitative deter-
mination of ADMA was performed using ADMA Elisa
kit (Immundiagnostik A.G, Stubenwald-Allee, Bensheim,
Germany).
Quantification of circulating Endothelial progenitor cells
Venous blood samples were collected after overnight fast
and abstention from smoking. EPCs were detected with
flow cytometry (surface expression of CD34 and KDR).
The antibody cocktail consisted of CD34+FITC (Beckman
Coulter, Fullerton, CA), and anti VEGFR (R&D Systems).
As the CD34 FITC antibody concentration was notspecified in the respective leaflet, both were mixed and
titrated in umbilical cord blood in order to define the dilu-
tions that minimized non-specific staining. Following
these preliminary experiments, 5ul of CD34 FITC and 3ul
of anti VEGFRPE were mixed and added to 50 ul of whole
blood. The fixed amount of blood used in combination
with BD Trucount tubesT (BD Biosciences, San Jose, CA,
USA) containing known numbers of microbeads, allowed
us to measure the absolute number of endothelial cells, as
described in the literature [23]. The blood specimen was
added to the antibody mix by reverse pipetting to improve
the accuracy and reproducibility of measurements. Follow-
ing incubation for 15 min at room temperature in the
dark, 450 ul of NH4Cl were added and incubated for
15min at room temperature in the dark. Each specimen
was stained in duplicate. 8000 beads of each sample
acquired on FacsCan (BD Biosciences) and control samples
were analyzed using BD Cell-Quest T software. Control
samples stained with isotype-matched antibodies were used
to exclude unspecific staining. The gating for CD34+ cells
was based on the basic ISHAGE protocol. The gated
CD34+ were examined for the expression of VEGFR anti-
gen and the absolute number of EPC was calculated
according to the formula: number of events in region con-
taining cell population/number of events in absolute count
bead region X number of beads per test/test volume.
Measurement of pulse wave velocity (PWV)
PWV was assessed by the Bramwell-Hill formula.
Carotid-femoral PWV was measured in all patients in
supine position after 5 minutes of rest using CompliorW
waveform analyzer (Colson, Les Lilas, France) [24]. Patients
were advised to abstain from smoking or eating for at least
3 hours and for at least 10 hours from alcohol consumption
before measurements, according to current recommenda-
tions for standardization of subject condition [25]. Pressure
waveforms of the Carotid and femoral arteries were
recorded using tonometry sensors at the left carotid and
femoral arteries. The waveform analyzer reports PWV of
the carotid- femoral arterial segments by simultaneously
measuring time intervals for pulse wave along the corre-
sponding arterial path. The path length was estimated
using a measuring tape. Three consecutive readings were
done for each patient, and the average was taken for
analysis. All measurements were performed by the same
examiner.
Statistical analysis
For the evaluation of the factors associated with PWV, a
standard two-step approach was followed: univariate and
multivariate analysis. At the univariate analysis, parametric
tests were appropriately implemented, given that PWV
followed the normal distribution (as attested by the
Shapiro-Wilk test, p=0.308). The factors whose associations
Table 1 Description of the study sample























Family history of DM
Yes 21 (42.0)
No 29 (58.0)
Continuous Variables Mean ± SD
EPCs-3 surface markers (cells/mL) 199 ±180
EPCs-2 surface markers (cells/mL) 262 ±210
ADMA (μmol/L) 0.76 ±0.16
Velocity (m/s) 9.1 ±1.4
Age (years) 50.6 ±11.2
BMI (kg/m2) 33.6 ±7.0
Waist circumference (cm) 110.4 ±18.0
Hip circumference (cm) 118.9 ±14.0
WHR 0.93 ±0.08
WHtR 0.65 ±0.10
Smoking (packyears) 20.1 ±39.8
SBP (mmHg) 140.6 ±16.1
DBP (mmHg) 85.4 ±10.2
MBP (mmHg) 103.8 ±11.3
HR (bpm) 77 ±11
Fasting glucose 107.5±10.1
HbA1c (%) 5.99±0.22
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exercise, smoking (yes vs. no and pack-years), subclassifica-
tion of pre-diabetes (IFG, IGT, IFG+IGT), intake of statins,
intake of renin-angiotensin-aldosterone (RAA) axis inhi-
bitors, intake of b-blockers, family history of diabetes
mellitus, EPC count, ADMA levels, age, BMI, waist
circumference, hip circumference, WHR, WHtR, mean
blood pressure (MBP), heart rate (HR), fasting plasma
glucose levels, HbA1c levels, insulin levels, HOMA-IR,
hs-CRP, total cholesterol, HDL-C, LDL-C, triglyceride
levels and GFR.
At the multivariate analysis, stepwise linear regression
was performed. As appropriate, factors proven signifi-
cant at the univariate analysis were tested in the stepwise
multivariate model as independent variables; a subset of
them (p<0.05) were appropriately retained during the
stepwise selection of variables. In case of collinear and
conceptually intertwined variables (such as total cholesterol
and LDL), alternative models were constructed. Normality
of the studentized (jackknifed) residuals was verified using
the Shapiro-Wilk test for each model. Statistical analysis
was performed using STATA 11.1 statistical software (Stata
Corporation, College Station, TX, USA).
Results
A total of 53 patients were included in this analysis of
whom 30 subjects (56.6%) were diagnosed with isolated
IFG, 9 subjects (17%) with isolated IGT (17%) and 14
with combined IFG-IGT (26.4%). Patients’ baseline char-
acteristics are presented in Table 1. Regarding gender,
54.7% of the subjects were women and 35.8% smokers
(n=19). Mean age was 50.6±11.2 (range: 31–67) years.
18 (34%) of patients were on therapy with RAS blockade
and 12 (22.6%) on statin therapy. In relation to exercise
status, 23 subjects (43.4%) reported physical exercise,
whereas 30 subjects (56.6%) did not.
Univariate correlation analyses were performed to
determine which variables were most closely associated
with arterial stiffness. In univariate analysis (Table 2)
exercise (p=0.009, Student’s t-test), age (r= +0.522,
p=0.0001), mean blood pressure (MBP) (r=+0.428,
p=0.002), fasting plasma glucose (r= +0.449, p=0.001),
total cholesterol (r=+0.601, p<0.0001), LDL cholesterol
(r=+0.672, p<0.0001), GFR (r= −0.491, p=0.0003), and
ADMA (r=+0.508, p=0.0002) were significantly asso-
ciated with PWV; the correlation with PWV was positive
for all aforementioned variables with the exception of
GFR and exercise. In contrast gender, CD34+ KDR+
cell counts, HbA1c levels, HOMA index, hs-CRP, anthropo-
metric variables, pre-diabetic status (IFG, IGTand combined
IFG and IGT) and the use of statins or any form of anti-
hypertensive treatment (p=0.186 for RAA inhibitors and
p=0.347 for beta –blockers) did not significantly correlate
with PWV.
Table 2 Results of the univariate analysis











Use of statins 0.656T
Yes 9.3±1.3
No 9.0±1.5
Continuous Variables PWV (mean±SD) r§ (p-value)
Age (years) +0.522 (0.0001)
<48 8.5±0.9
≥48 9.6±1.6
MBP (mmHg) +0.428 (0.002)
<106.3 8.1±0.8
≥106.3 10.0±1.3
Total cholesterol (mg/dL) +0.601 (<0.0001)
<196 8.2±1.1
≥196 9.9±1.2
LDL (mg/dL) +0.672 (<0.0001)
<118.4 8.0±0.7
≥118.4 10.1±1.2
GFR (mL/min) −0.491 (0.0003)
<77 9.6±1.3
≥77 8.5±1.3
ADMA (μmol/L) +0.508 (0.0002)
<0.757 8.1±0.8
≥0.757 9.8±1.3












Table 2 Results of the univariate analysis (Continued)
Fasting glucose (mg/dL) +0.449 (0.001)
<107 8.6±1.7
≥107 9.5±1.0
HbA1c (%) +0.006 (0.967)
<6 9.0±1.2
≥6 9.2±1.6
hs-CRP (mg/L) +0.018 (0.907)
<3.89 8.9±1.5
≥3.89 9.4±1.4
Continuous variables have been presented as <median and ≥median for
purely descriptive reasons; their continuous nature has been appropriately
taken into account at the univariate tests; T: Student’s t-test; A: Analysis of
variance (ANOVA); §: Pearson’s correlation coefficient.
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the fact that EPC numbers were significantly correlated
with mean arterial pressure (rho=−0.355, p=0.011), hs-CRP
(rho=−0.307, p=0.030), HOMA-IR (rho=−0.350, p=0.010),
waist circumference (rho=−0.446, p=0.001) and total
cholesterol (rho=+0.323, p=0.018).
ADMA was not significantly associated with fasting
glucose (Spearman’s rho = +0.070, p=0.619), or HbA1c
(Spearman’s rho = −0.002, p=0.988). In contrast ADMA
levels were significantly associated with WC (rho=+0.310,
p=0.029), median arterial pressure (rho=+0.645,p=0.001),
and statin intake (0.67±0.09 μmol/L for subjects taking
statins, but 0.78±0.16 μmol/L for those not taking statins,
p=0.018 Mann–Whitney-Wilcoxon test for independent
samples). A trend towards a positive association between
higher ADMA levels and older age was noted (Spearman’s
rho=+0.244,p=0.079).
In order to establish which of these correlates were
independent predictors of arterial stiffness, multivariate
stepwise regression analysis was performed (Table 3).
Given the fact that total cholesterol and LDL were colli-
nearly (r=+0.943, p<0.0001) and conceptually interwoven,
two alternative models were constructed, beginning with
exercise, age, MBP, GFR, ADMA and one of the two collin-
ear variables (LDL-C or total cholesterol). During the step-
wise approach, age, fasting plasma glucose, MBP and GFR
lost their statistical significance in both cases. As a result,
PWV was found to correlate independently and positively
with LDL-Cholesterol (coefficient= +0.03, 95%CI: +0.02 to
+0.04) and ADMA levels (coefficient= +2.57, 95%CI: +0.84
to +4.31) and negatively with exercise (coefficient= −1.04,
95%CI: -1.53 to −0.55). The same results were replicated in
beginning of the analysis with total cholesterol instead of
LDL (Table 3).
Discussion
In the present study, we investigated the relationship
between cardiovascular risk factors and arterial stiffness,
Table 3 Results of the stepwise multivariate linear regression analysis
Variables Category or Increment Coefficient (95%CI) p
Model 1
(Beginning with exercise, age, MBP, LDL, fasting glucose, GFR, ADMA)
LDL 1mg/dL increase +0.03 (+0.02 to +0.04) <0.001
Exercise Yes vs. no −1.04 (−1.53 to −0.55) <0.001
ADMA 1μmol/L increase +2.57 (+0.84 to +4.31) 0.004
Model 2
(Beginning with exercise, age, MBP, total cholesterol, fasting glucose GFR, ADMA)
Total cholesterol 1mg/dL increase +0.03 (+0.02 to +0.04) <0.001
Exercise Yes vs. no −0.91 (−1.41 to −0.40) 0.001
ADMA 1μmol/L increase +3.80 (+2.08 to +5.53) <0.001
Variables independently associated with PWV.
Protopsaltis et al. Cardiovascular Diabetology 2012, 11:141 Page 6 of 9
http://www.cardiab.com/content/11/1/141with emphasis placed on novel risk factors, as ADMA
and EPCs, among subjects with pre-diabetes.
From current knowledge, arterial stiffness represents
the combined cumulative effect of traditional cardiovas-
cular risk factors, with the full repertoire of factors
implicated to be greatly obscure though. Arterial stiff-
ness is an established predictor of cardiovascular disease,
and its increase is associated with a 48% increase of car-
diovascular disease risk [26].
According to the results of the present study levels of
ADMA, LDL-C, as well as exercise, significantly and
directly correlated with PWV in pre-diabetic subjects.
The finding of LDL-C correlation with PWV is in
accordance with the findings of others [27]. In contrast
with the above, other researchers failed to demonstrate
any association between aortic stiffness and plasma
lipoprotein levels [28]. These conflicting results can be
attributed to the different atherosclerotic burden among
studied populations, the evaluation of different fractions
of lipoproteins, the confounding effect of hypertension,
and the use of different techniques/indices for the evalu-
ation of large artery stiffness.
At the molecular level, high LDL-C levels induce
endothelial cell dysfunction with subsequent decreased
NO bioavailability due to impaired L-arginine transport
and metabolism and eNOS uncoupling. Peroxynitrite,
the major uncoupling byproduct of eNOs, has been
reported to directly damage elastin [11,29,30]. The ensu-
ing decreased NO bioavailability, also increases vascular
smooth muscle cell tone, which further aggravates arter-
ial stiffness [11].
Although arterial stiffness could potentially be improved
with HMG-coA enzyme inhibition by statins [31] in the
present study, a lack of association between statin therapy
and PWV was observed. However our findings are in
agreement with previously published studies [32].
Several crucial studies have yielded contradictory
results in relation to the association of ADMA with aPWV. In our study, ADMA increased arterial stiffness
and this is also in agreement with the results of others
[18]. Given that NO participates in maintaining the
structure of blood vessels [11], it is not surprising that
increased expression of a natural nitric oxide synthase
(eNOS) inhibitor, such as ADMA, has been linked to
vascular stiffening.
In contrast, in the PREVENCION study, ADMA and
NMMA (N-MonoMethyl Arginine) were not associated
with large artery stiffness [33]. The discrepancies
between our analysis and PREVENCION study could be
attributed to differences in study design and population
characteristics. For example, the sample population in
our analysis consisted of individuals with pre-diabetes,
carrying a higher atherosclerotic burden. Moreover, in
our study we investigated the correlation of cf-PWV
with conventional risk factors after multivariate selection
of variables including exercise, number of EPC, HOMA
index, and use of antihypertensive or hypolipidemic
treatment, which were not performed in the PREVEN-
CION study.
In the present study, we did not observe any correl-
ation between EPC count and arterial stiffness. In agree-
ment with our findings, Palombo et al. [27] reported no
significant correlation between CD34+/KDR+ counts
and c-f PWV in type 1 diabetics. In the same study
LDL-C was proved to be independent predictor of c-f
PWV in agreement with our findings. Although Yang
et al. [34] reported that impaired EPC activity was asso-
ciated with reduced elasticity among hypertensive sub-
jects, no significant correlation was again demonstrated
between the number of circulating EPCs and arterial
elasticity indices. It should be underlined though, that
our results are not fully comparable with those of the
previous study, since subjects with diabetes and smokers
were excluded.
In contrast with the above, reduced numbers of circu-
lating EPC have been associated with impaired arterial
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EPC recruitment from bone marrow is NO [13]
mediated, it is expected that, as endothelial dysfunction
worsens in parallel with glucose levels [36], EPC count
would also decrease. Consequently our results are not
totally comparable to others, since our study population
consists of pre-diabetic individuals.
According to our findings, HbA1c levels did not cor-
relate with PWV at univariate analysis. Fasting glucose
levels positively and significantly correlated with PWV at
univariate analysis but this correlation was lost at multi-
variate analysis. A trend for increased PWV across pre-
diabetic categories was observed that did not reach
statistical significance though and the above is most pos-
sibly due to the small sample size in the present study. It
should be noted though that previous studies have
shown that hyperglycemia and hyperinsulinemia explain
only 30% of arterial changes associated with glucose in-
tolerance [37] and in non-diabetic individuals with lower
levels of hyperglycemia no definitive correlation has
been proved between arterial stiffness and IGT [38].
From the theoretic point of view it has also been pro-
posed that arterial stiffness in pre-diabetic individuals is,
at least partially, NO mediated [38]. Insulin resistance
is associated with decreased NO bioavailability while
hyperinsulinemia contributes to proliferation of arterial
smooth muscle cells [39].
Our results demonstrate that among subjects with
pre-diabetes moderate physical activity for at least
150 min per week can reverse arterial stiffness. In agree-
ment with this finding Tanaka et al. [40] have also
reported that high levels of physical activity may prevent
increases in arterial stiffness in elderly women. In the
same study, it was also reported that in addition to
aerobic fitness, plasma total cholesterol and plasma
LDL-cholesterol levels were significant determinants of
central arterial stiffness.
In our sample of prediabetic patients age significantly
correlated with increased arterial stiffness at univariate
analysis but at multivariate analysis this correlation lost
significance. However as previously reported, arterial
elasticity is not determined only by the structural
components of the vessel wall, but NO can also modify
arterial stiffness. Indeed Ngo et al. reported that NO
synthesis may represent the basis for increased arterial
stiffness in ageing individuals [18]. Even though age is a
major determinant of arterial stiffness, several studies
reported that increase in large artery stiffness, follows an
non linear evolution, implying that an increase in PWV
may be observed over the age of 55 years; indeed, in our
sample mean age was 50.2 years, well below the 55 year-
threshold [41-43].
Although blood pressure is traditionally considered a
major determinant of the arterial stiffness, suchcorrelation did not persist in the present study at the
multivariate analysis. High levels of systolic blood
pressure are believed to increase arterial stiffness due
to structural and functional alterations in the arterial
media and higher systolic blood pressure levels have
been connected with greater increases in arterial stiff-
ness in several prospective studies [44]. Although the
relationship of blood pressure with vascular stiffness
seems to be bidirectional, investigators of the Framing-
ham Offspring [45] cohort, concluded that vascular
stiffness is a precursor rather than the result of hyper-
tension. Other studies have also failed to document
SBP as an independent predictor of increased arterial
stiffness [46-49] and it has been proposed that
increased PWV lays in the basis of increased arterial
pressure and not the opposite on a long-term basis.
From this point of view the cross sectional nature of
our study might have obscured causality between arter-
ial stiffness and MBP that needs time to develop.
A limitation of our study pertains to the relatively
small population size. Due to the small sample size,
certain secondary observations may not have reached
statistical significance; nevertheless, the fact that statisti-
cally significant associations emerged and persisted at
the multivariate analysis, points to the validity and
robustness of the findings presented herein. In addition,
the cross-sectional study design does not allow the
substantiation of causality, the latter necessitating pro-
spective cohort studies.
Unfortunately in this analysis, qualitative alterations of
EPC, such as colony formation, migration or adhesion,
were not examined, but in most cases, the number and
the functionality of EPC are essentially two sides of the
same coin; quantitative and qualitative EPC properties
are indeed co-regulated by the same molecular pathways,
and consequently decreased EPC count is commonly
accompanied with dysfunction [50].
Finally, the use of a control group was not deemed
necessary, since the main objective of the present study
has been the investigation of correlations between novel
and traditional cardiovascular risk factors and arterial
stiffness in a specific subpopulation (prediabetics), in
which the major, independent determinants of PWV
were sought. The validation and replication of previously
documented differences (such as comparisons of indivi-
duals with pre-diabetes versus controls) was considered
redundant and was not performed. Indeed according to
the findings of the Hoorn study, severity of arterial stiff-
ness seems to correlate with degree of glucose metabol-
ism impairment with IFG and IGT patients to exhibit
increased arterial stiffness that is intermediate between
type II frank diabetics and subjects with normal glucose
tolerance [5,37] and the above findings have been
verified by other studies [6].
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been directly connected with reduced numbers of circu-
lating EPCs compared with normal glucose tolerance
status in several studies [13,14]. Numerous studies have
also established that ADMA levels are increased in states
of impaired glucose metabolism, in relation to normal
subjects, and this increase seems to positively correlate
with glycemic category and metabolic control [51,52].
Nevertheless the lack of a control population may be
considered a major limitation of the present study.
Indeed, an age matched control group may have signifi-
cantly contributed to the comparison of novel markers
(such as EPC and ADMA) between patients with pre-
diabetes and healthy subjects. The control group could
also have proven that all methods yielded results com-
parable with the literature. Future studies adopting con-
trol groups seem necessary in our setting so to further
elaborate and validate the aforementioned findings. In
our knowledge, this is the first study to investigate the
correlation of traditional and novel cardiovascular risk
factors, as AMDA and endothelial progenitor cells and
arterial stiffness, as evaluated by PWV, in pre-diabetic
individuals.Conclusion
In conclusion according to the findings of the present
study LDL-cholesterol levels, ADMA levels and physical
exercise are strongly associated with PWV among pre-
diabetic subjects. In contrast the number of EPCs did
not correlate with arterial stiffness. Prospective studies
are needed to further elucidate the mechanisms under-
lying these associations, for determining the impact of
lifestyle modifications, or the effects of antilipidemic
medications, or insulin sensitizing drugs on PWV
[53,54]. Cardiovascular disease is so closely linked to
increased PWV, so that identification of the predisposing
factors of the latter will improve not only treatment
efficacy, focusing on specific destiffening drugs, but also
the quality of life of pre-diabetic individuals.
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